-+ 0.00%
-+ 0.00%
-+ 0.00%

Changchun Hi-Tech (000661.SZ) subsidiary GenSci 133 injection clinical trial application approved

Zhitongcaijing·09/04/2026 08:33:50
Listen to the news

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registration of domestically produced drugs for GenSci133 injection was approved.

According to reports, GenScI133 injection is a parathyroid hormone (PTH) analog and antinuclear factor kappa B receptor activator (RANKL) antibody fusion protein independently developed by Jinsai Pharmaceutical. It belongs to class 1 of therapeutic biological products and is intended to treat osteoporosis. If the subsidiary's clinical trial application progresses smoothly, it will help the company broaden its business structure, optimize the product structure, enrich and improve the product line layout in the field of endocrine metabolism, and enhance the company's core competitiveness.